Critical mechanisms employed by BET inhibitors to fight multiple myeloma involve the inhibition of MYC transcription and MYC carcinogenesis (69), both of which are also caused by I-BET151 that exerts its inhibitory activity by attenuating the chromatin recruitment of CDK9 in a BRD2/3/4-dependent manner, which caused transcription inhibition of MYC and MYC carcinogenic programs. The gene discussed is MYC; the disease is plasma cell myeloma.